Trial of PI-88 With Docetaxel in Advanced Non-Small-Cell Lung Cancer (NSCLC)

PHASE2CompletedINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

February 29, 2004

Study Completion Date

July 31, 2006

Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
DRUG

docetaxel

DRUG

PI-88

Trial Locations (13)

2031

Prince of Wales Hospital, Randwick

2050

Sydney Cancer Centre, Royal Prince Alfred Hospital, Camperdown

2065

Royal North Shore Hospital, St Leonards

2077

Sydney Haematology and Oncology Clinics, Hornsby

2298

Newcastle Mater Misericordiae Hospital, Waratah

3187

The Alfred Hospital, Prahran

3690

Border Medical Oncology, Wodonga

4032

Prince Charles Hospital, Chermside

4101

Mater Hospital, South Brisbane

4102

Princess Alexandra Hospital, Woolloongabba

4560

Nambour General Hospital, Nambour

5011

The Queen Elizabeth Hospital, Woodville

6009

Sir Charles Gairdner Hospital, Nedlands

All Listed Sponsors
collaborator

Medigen Biotechnology Corporation

INDUSTRY

lead

Cellxpert Biotechnology Corp.

INDUSTRY